The Impact of Ferritin Levels on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation: Real-Life Data

Objective: This retrospective study aimed to evaluate the effects of ferritin level on outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) including the neutrophil/platelet engraftment, febrile neutropenia, transplant related mortality (TRM), graft versus host disease (GvHD), sinusoidal obstruction syndrome (SOS)/veno-occlusive disease (VOD) and overall survival (OS). Materials and Methods: Sixty-nine patients with ferritin values measured at the beginning of allo-HSCT between 2018 - 2021 were enrolled in this study. The ferritin cut-off value was determined as 1000ng/mL and the patients were divided into 2 groups (.05). The median OS in patients with ferritin level ≥1000 ng/ mL and ferritin level <1000 ng/mL 4 months (95% CI: 1.4-6.6) and 8 months (95% CI: 0-24.2), respectively. There was no statistically significant correlation between ferritin value and OS (p=0.206). There was no statistically significant difference between the ferritin groups on both acute and chronic GvHD (p=0.713 and p=0.999, respectively). Conclusion: Our study did not demonstrate any negative effects of serum ferritin levels on allo-HSCT outcomes; however, large-scale prospective studies are needed to clarify the effect of iron overload on the outcomes of allo-HSCT.